解除干扰素信号与抗原呈递的耦联以克服黑色素瘤JAK1缺失所致免疫治疗耐药
该研究在小鼠B16黑色素瘤中构建了模拟患者获得性免疫检查点阻断(ICB)耐药的干扰素(IFN)信号缺陷模型。缺失Jak1或Jak2的肿瘤对ICB无应答;过继性T细胞治疗(ACT)对Jak2敲除肿瘤有效,但对Jak1敲除肿瘤无效,原因是MHC I类分子基础表达低且依赖IFN信号。过表达NLRC5或瘤内递送BO-112均可恢复ACT对B16-Jak1敲除肿瘤的疗效。
要点
- 肿瘤IFN信号缺陷导致ICB耐药,但ACT仍可能有效,取决于MHC I表达
- Jak1缺失同时破坏I型和II型IFN信号,MHC I低表达,ACT无效
- BO-112经dsRNA感应激活NF-κB诱导MHC I,不依赖IFN信号和NLRC5
核心结论
- 肿瘤IFN信号缺失时,MHC I表达是ACT疗效的必要且充分条件。
- 对因IFN信号缺陷而MHC I表达低的肿瘤,BO-112激活dsRNA传感器可恢复ACT疗效。
研究设计与样本
- 在B16小鼠黑色素瘤中构建模拟患者获得性ICB耐药的IFN信号缺陷模型。
- 采用遗传学和药理学方法解除MHC I对IFN信号的依赖并恢复其表达。
主要发现
- 缺失Jak1或Jak2的肿瘤对ICB无应答。
- ACT对Jak2敲除肿瘤有效,但对Jak1敲除肿瘤无效,后者I型和II型肿瘤IFN信号均缺陷。
- B16基础MHC I表达低,且MHC I表达依赖I型或II型IFN信号。
- 过表达NLRC5与瘤内递送BO-112通过各自独立机制恢复ACT对B16-Jak1敲除肿瘤的疗效。
- BO-112经蛋白激酶R和Toll样受体3激活dsRNA感应,经NF-κB诱导MHC I,不依赖IFN信号和NLRC5。
临床怎么用
- 对IFN信号缺陷、MHC I低表达的肿瘤,可考虑以恢复MHC I表达为策略增强ACT疗效。
- BO-112瘤内递送联合ACT是IFN信号缺陷肿瘤的潜在转化方向。
局限性
- 证据主要来自B16小鼠黑色素瘤模型,尚需临床验证。
- 原文摘要未报告人体试验数据、样本量与统计阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Defects in tumor-intrinsic interferon (IFN) signaling result in failure of immune checkpoint blockade (ICB) against cancer, but these tumors may still maintain sensitivity to T cell-based adoptive cell therapy (ACT). We generated models of IFN signaling defects in B16 murine melanoma observed in patients with acquired resistance to ICB. Tumors lacking Jak1 or Jak2 did not respond to ICB, whereas ACT was effective against Jak2 KO tumors, but not Jak1 KO tumors, where both type I and II tumor IFN signaling were defective. This was a direct result of low baseline class I major histocompatibility complex (MHC I) expression in B16 and the dependency of MHC I expression on either type I or type II IFN signaling. We used genetic and pharmacologic approaches to uncouple this dependency and restore MHC I expression. Through independent mechanisms, overexpression of NLRC5 (nucleotide-binding oligomerization domain-like receptor family caspase recruitment domain containing 5) and intratumoral delivery of BO-112, a potent nanoplexed version of polyinosinic:polycytidylic acid (poly I:C), each restored the efficacy of ACT against B16-Jak1 KO tumors. BO-112 activated double-stranded RNA (dsRNA) sensing (via protein kinase R and Toll-like receptor 3) and induced MHC I expression via nuclear factor κB, independent of both IFN signaling and NLRC5. In summary, we demonstrated that in the absence of tumor IFN signaling, MHC I expression is essential and sufficient for the efficacy of ACT. For tumors lacking MHC I expression due to deficient IFN signaling, activation of dsRNA sensors by BO-112 affords an alternative approach to restore the efficacy of ACT.
引用
- Kalbasi A, Tariveranmoshabad M, Hakimi K, et al. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Sci Transl Med. 2020. PMID: 33055240. doi:10.1126/scitranslmed.abb0152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。